当前位置:首页 / 周期蛋白依赖性激酶抑制因子3在喉鳞状细胞癌组织中的表达及临床意义
论著·临床研究 | 更新时间:2024-05-09
|
周期蛋白依赖性激酶抑制因子3在喉鳞状细胞癌组织中的表达及临床意义
Expression and clinical significance of cyclin⁃dependent kinase inhibitor 3 in laryngeal squamous cell cancerous tissues

广西医学 页码:231-235

作者机构:刘淑佳,在读硕士研究生,住院医师,研究方向为鼻部恶性肿瘤的防治。

基金信息:河南省医学科技攻关计划联合共建立项项目(LHGJ20200508)

DOI:10.11675/j.issn.0253⁃4304.2024.02.09

  • 中文简介
  • 英文简介
  • 参考文献

目的 探讨周期蛋白依赖性激酶抑制因子3(CDKN3)在喉鳞状细胞癌(LSCC)组织中的表达水平,分析其与LSCC患者临床病理特征及预后的关系。方法 收集83例LSCC患者的癌组织和对应的癌旁正常组织,采用免疫组织化学法检测组织中CDKN3的表达水平。比较不同临床病理特征患者LSCC组织中CDKN3表达水平,以及不同CDKN3表达水平的患者的总体生存率。根据患者生存情况,将其分为死亡组(n =11)和生存组(n =72),比较两组的临床病理特征及LSCC组织中CDKN3表达水平。采用Logistic回归模型分析LSCC患者生存情况的影响因素。结果 LSCC组织CDKN3表达水平高于癌旁正常组织(P<0.05)。TNM分期为Ⅲ期+Ⅳ期、T3期+T4期、有淋巴结转移情况的患者LSCC组织中CDKN3的表达水平更高(P<0.05)。CDKN3低表达患者的总体生存率高于CDKN3高表达者(P<0.05)。生存组TNM分期为Ⅰ期+Ⅱ期、 无淋巴结转移、T1期+T2期、CDKN3表达水平<0.029的患者比例高于死亡组(P<0.05)。多因素Logistic回归分析结果提示淋巴结转移是影响LSCC患者生存情况的影响因素(P<0.05)。结论 LSCC组织中CDKN3表达水平升高,其表达水平与患者临床分期和淋巴结转移有关,且CDKN3高表达患者的总体生存率较低。

Objective To investigate the expression of cyclin⁃dependent kinase inhibitor 3 (CDKN3) in laryngeal squamous cell carcinoma (LSCC) tissues, and to analyze its relation with clinicopathological features and prognosis of LSCC patients. Methods Cancerous and corresponding paracancerous normal tissues of 83 LSCC patients were collected, and the expression of CDKN3 in tissues was detected by using the immunohistochemical method. CDKN3 expression in LSCC tissues was compared between patients with different clinicopathological features, and the overall survival rate was compared between patients with different CDKN3 expressions. According to patients' survival status, they were assigned to death group (n=11) or survival group (n=72), clinicopathological features and CDKN3 expression in LSCC tissues were compared between the two groups. The influencing factors for LSCC patients' survival status were analyzed by employing the Logistic regression model. Results CDKN3 expression in LSCC tissues was higher than that in paracancerous normal tissues (P<0.05). Patients with TNM stage in Ⅲ+Ⅳ, stage in T3+T4, and with the presence of lymph node metastasis obtained a higher CDKN3 expression in LSCC tissues (P<0.05). The overall survival rate of patients with low⁃expressed CDKN3 was higher than that of patients with high⁃expressed CDKN3 (P<0.05). The survival group exhibited higher proportions of patients with TNM stage in Ⅰ+Ⅱ, without lymph node metastasis, with stage in T1+T2, and with CDKN3 expression<0.029 as compared with the death group (P<0.05). The results of multivariate Logistic regression analysis indicated that lymph node metastasis was the influencing factor for affecting LSCC patients' survival status (P<0.05). Conclusion CDKN3 expression is elevated in LSCC tissues, its expression is related to patients' clinical stage and lymph node metastasis, and the overall survival rate of patients with high⁃expressed CDKN3 is relatively low.

93

浏览量

11

下载量

0

CSCD

工具集